Pereira Leal Ana Ediléia Barbosa, de Lavor Érica Martins, de Menezes Barbosa Jackson, de Moura Fontes Araújo Maria Taís, Dos Santos Cerqueira Alves Cristiane, de Oliveira Júnior Raimundo Gonçalves, de Lima Ádley Antonini Neves, da Silva Almeida Jackson Roberto Guedes
Postgraduate Program in Biotechnology, State University of Feira de Santana, Feira de Santana, Brazil.
Center for Studies and Research of Medicinal Plants, Federal University of San Francisco Valley, Petrolina, Brazil.
Curr Top Med Chem. 2022;22(28):2315-2328. doi: 10.2174/1568026622666220819160923.
Passiflora L. is a genus belonging to the Passifloraceae family, with many species widely used in folk medicine and several pharmacological activities described in the scientific literature, being a major target for the development of new therapeutic products. Studies have identified several bioactive compounds in their composition as responsible for these activities, mainly C-glycoside flavonoids.
The aim of this study was to carry out a review of patents related to the genus and its application in several pharmacological activities, important for the development of new drugs and formulations.
The search was carried out in 5 specialized databases, INPI, EPO, WIPO, Latipat and Derwent, using the term 'Passiflora' combined with 'A61K and A61P', subclasses of section A of the International Patent Classification (IPC), which are destined to medical, dental or hygienic purposes, and therapeutic activity of chemical compounds or medicinal preparation, respectively.
1,198 patents citing the genus in the title or abstract have been found, 508 being duplicates. After exclusion and inclusion criteria, 23 patents written in English, Portuguese and Spanish were selected, which demonstrated biological assays in vivo with species of Passiflora as the only active constituent or incorporated in formulations with other compounds.
The findings of this search showed growing interest in research and industrial areas in the pharmaceutical development with species of Passiflora, suggesting that the different bioactive compounds present in the genus can be considered as an important tool for the development of new effective and safe products with pharmacological potential.
西番莲属植物属于西番莲科，许多物种在民间医学中广泛使用，科学文献中也描述了其多种药理活性，是新型治疗产品开发的主要目标。研究已在其成分中鉴定出几种生物活性化合物，认为这些化合物是导致这些活性的原因，主要是C - 糖苷类黄酮。
本研究的目的是对与该属及其在多种药理活性中的应用相关的专利进行综述，这对新药和制剂的开发很重要。
在5个专业数据库（巴西国家工业产权局数据库、欧洲专利局数据库、世界知识产权组织数据库、拉丁美洲专利数据库和德温特数据库）中进行检索，使用术语“西番莲属”与“国际专利分类（IPC）A部的A61K和A61P”组合，A61K和A61P分别用于医疗、牙科或卫生目的以及化合物或药物制剂的治疗活性。
已发现1198项在标题或摘要中引用该属的专利，其中508项为重复专利。经过排除和纳入标准后，选择了23项用英语、葡萄牙语和西班牙语撰写的专利，这些专利展示了以西番莲属物种作为唯一活性成分或与其他化合物一起制成制剂的体内生物学试验。
本次检索结果表明，制药开发的研究和工业领域对西番莲属物种的兴趣日益增加，这表明该属中存在的不同生物活性化合物可被视为开发具有药理潜力的新型有效和安全产品的重要工具。
